What is ROIV stock forecast?

Roivant Sciences Ltd forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

ROIV

Roivant Sciences Ltd

NASDAQ: ROIV · HEALTHCARE · BIOTECHNOLOGY

$27.52

-0.90% today

Updated 2026-04-29

Market cap

$19.70B

P/E ratio

—

P/S ratio

1,479.80x

EPS (TTM)

$-1.17

Dividend yield

—

52W range

$11 – $30

Volume

5.5M

Market cap

$19.70B

P/E ratio

—

P/S ratio

1,479.80x

EPS (TTM)

$-1.17

Dividend yield

—

52W range

$11 – $30

Volume

5.5M

Roivant Sciences Ltd (ROIV) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$27.52

Consensus

$27.56

+0.15%

2030 Target

$22.30

-18.97%

DCF

—

Current price

$27.52

Analyst consensus

$27.56

+0.15%

2030 Target

$22.30

-18.97%

Intrinsic (DCF)

—

8 analysts:

2 Buy1 Hold0 Sell

Management guidance

No specific revenue targets disclosed by management. CEO guidance focuses on pipeline execution milestones (brepocitinib PDUFA Q3 2026, PHocus topline data H2 2026) rather than revenue projections. Company emphasizes clinical readouts and regulatory approvals as near-term catalysts rather than committing to specific revenue figures.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$36.24

$1.3B Rev × 20x P/S

Base case (2030)

$22.30

$1.3B Rev × 12x P/S

Bear case (2030)

$13.94

$1.3B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$0.1B	$0.0B	$0.0B	$0.0B	$0.2B	$0.6B	$0.9B	$1.3B
Revenue growth	—	-46.6%	-11.2%	-65.5%	1750.0%	197.0%	67.0%	39.0%
EPS	—	$-1.27	$-0.80	$-1.23	$-0.65	$0.15	$0.85	$1.42
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$0.00	$2.79	$8.36	$13.94	$22.30

Catalysts & risks

Growth catalysts

+ Brepocitinib FDA PDUFA decision Q3 2026 for dermatomyositis (Priority Review, positive Phase 3 VALOR data published in NEJM)

+ Pulmovant mosliciguat Phase 2 topline data H2 2026 for pulmonary hypertension (PHocus trial completed enrollment)

+ Genevant/Arbutus $2.25B Moderna settlement provides significant capital for pipeline acceleration and potential commercialization funding

Key risks

- Execution risk on late-stage trials (batoclimab failed Phase 3 TED endpoint in April 2026, showing binary clinical outcome risk)

- Brepocitinib showed increased serious infections in Phase 3 (safety profile may limit commercial potential despite efficacy)

- Revenue collapse in FY2026 (-65% guidance vs FY2025) reflects discontinuation of prior partnership or product revenue stream; new commercial revenue dependent entirely on pipeline approvals post-2026

Methodology

Roivant Sciences Ltd's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 8 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.